Perspective Therapeutics (CATX) Earnings Date, Estimates & Call Transcripts $13.17 -1.93 (-12.78%) (As of 03:03 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Earnings SummaryLatest Earnings DateAug. 12EstimatedActual EPS (Aug. 12) -$0.17 Beat By $0.04 Consensus EPS (Aug. 12) -$0.21 Get Perspective Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for CATX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCATX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CATX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Market JARBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a shooter's exact location.Don't miss out. Get the full details on this AI bargain. Perspective Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.02)($0.02)($0.02)Q2 20241($0.21)($0.21)($0.21)Q3 20241($0.19)($0.19)($0.19)Q4 20241($0.21)($0.21)($0.21)FY 20244($0.63)($0.63)($0.63)CATX Earnings Date and InformationPerspective Therapeutics last announced its earnings results on August 12th, 2024. The reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04. The company had revenue of $0.53 million for the quarter. Perspective Therapeutics has generated $0.00 earnings per share over the last year. Earnings for Perspective Therapeutics are expected to decrease in the coming year, from ($0.86) to ($0.99) per share. Read More Perspective Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks8/12/2024Q2 2024($0.21)($0.17)+$0.04($0.16)-$0.53 million5/15/2024Q1 2024($0.30)($0.20)+$0.10($0.02)-$0.33 million 11/14/2023Q3 2023($0.40)($0.40)-($0.04)$2.20 million$2.19 million 8/11/2023Q2 2023($0.30)($0.40)($0.10)($0.04)$2.61 million$2.09 million 2/16/2023Q4 2022($0.10)($0.20)($0.10)($0.02)$4.20 million$1.84 million 11/10/2022Q3 2022($0.10)($0.30)($0.20)($0.03)-$1.72 million Get the Latest News and Ratings for CATX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 9/28/2022Q2 2022($0.10)($0.10)-($0.01)$2.89 million$2.51 million 5/10/2022Q1 2022($0.10)($0.10)-($0.01)$3.15 million$2.91 million 2/8/2022Q4 2021($0.10)($0.10)-($0.01)$3.06 million$2.82 million 11/10/2021Q3 2021($0.10)($0.20)($0.10)($0.02)$2.58 million$2.56 million 9/21/2021Q2 2021($0.10)($0.10)-($0.01)$2.61 million$2.71 million 5/13/2021Q1 2021($0.10)($0.10)-($0.01)$2.44 million$2.60 million2/9/2021Q4 2020($0.10)($0.10)-($0.01)$2.36 million$2.36 million11/10/2020Q3 2020($0.10)($0.10)-($0.01)$3.03 million$2.38 million9/17/2020Q2 2020($0.10)($0.20)($0.10)($0.02)$2.77 million$2.28 million5/12/2020Q1 2020($0.10)($0.10)-($0.01)$2.76 million$2.88 million2/11/2020Q4 2019($0.10)($0.10)-($0.01)$2.39 million$2.21 million11/12/2019Q3 2019($0.20)($0.10)+$0.10($0.01)$2.23 million$2.32 million9/24/2019Q2 2019($0.20)($0.20)-($0.02)$1.82 million$1.92 million Perspective Therapeutics Earnings - Frequently Asked Questions When did Perspective Therapeutics announce their last quarterly earnings? Perspective Therapeutics (NYSE:CATX) last announced its quarterly earning data on Monday, August 12, 2024. Learn more on CATX's earnings history. Did Perspective Therapeutics beat their earnings estimates last quarter? In the previous quarter, Perspective Therapeutics (NYSE:CATX) reported ($0.17) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.21) by $0.04. Learn more on analysts' earnings estimate vs. CATX's actual earnings. How much revenue does Perspective Therapeutics generate each year? Perspective Therapeutics (NYSE:CATX) has a recorded annual revenue of $1.43 million. How much profit does Perspective Therapeutics generate each year? Perspective Therapeutics (NYSE:CATX) has a recorded net income of -$46.51 million. CATX has generated $0.00 earnings per share over the last four quarters. What is Perspective Therapeutics's EPS forecast for next year? Perspective Therapeutics's earnings are expected to decrease from ($0.86) per share to ($0.99) per share in the next year. More Earnings Resources from MarketBeat Related Companies: AXNX Earnings Results NVST Earnings Results TNDM Earnings Results NARI Earnings Results LIVN Earnings Results ENOV Earnings Results CNMD Earnings Results IRTC Earnings Results RXST Earnings Results NVCR Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit OutlookDon’t Count Out CrowdStrike Yet: Key Insights from Q2 Earnings This page (NYSE:CATX) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CATX Stock Alerts